Fulcrum Therapeutics (FULC) Stock Price, Quote, News & History | Benzinga

Fulcrum Therapeutics Inc (FULC) Stock Price, Quote, News & History

FULCNASDAQ

Trade with Public

Trade with Public

$3.71

-0.015-0.4%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.75

Close

-

Volume / Avg.

1.00M / 2.56M

Day Range

$3.64 - $3.76

52 Wk Range

2.83 - 15.74

Market Cap

$282.68M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

8.78%

Days to Cover

4.54

Recent Fulcrum Therapeutics, Inc. News

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.

Vandana Singh

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.

Avi Kapoor

CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO target raised, PRAX target lowered, NU target cut.

Avi Kapoor

This Goldman Sachs Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC, INTU, NU.

Avi Kapoor

Why Hewlett Packard Enterprise Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. Top losers are FULC, JZ, and more.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-65.78M

Investing Cash Flow (TTM)

-96.87M

Financing Cash Flow (TTM)

168.41M

Free Cash Flow (TTM)

-66.14M

Capital Expenditure (TTM)

-365.00K

Net Change in Cash (TTM)

5.77M

Analyst Trends and Forecast

2

2

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.5

Sell

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$29.35M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.91

Earnings Yield % (TTM)

-32.48%

Earnings Yield % (FWD)

-23.76%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.07

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$48.47M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.75

Close

-

Volume / Avg.

1.00M / 2.56M

Day Range

$3.64 - $3.76

52 Wk Range

2.83 - 15.74

Market Cap

$282.68M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

8.78%

Days to Cover

4.54

About

Sector

Health Care

Industry

Pharmaceuticals

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Fulcrum Therapeutics (FULC) stock?

A

You can purchase shares of Fulcrum Therapeutics (NASDAQ:FULC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Fulcrum Therapeutics (FULC) competitors?

A

Other companies in Fulcrum Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Fulcrum Therapeutics (FULC) stock?

A

Fulcrum Therapeutics has a consensus price target of $8.00.

Q

What is the current price for Fulcrum Therapeutics (FULC)?

A

The stock price for Fulcrum Therapeutics (NASDAQ: FULC) is $3.705 last updated August 13, 2026 at 3:46 PM EDT.

Q

Does Fulcrum Therapeutics (FULC) pay a dividend?

A

There are no upcoming dividends for Fulcrum Therapeutics.

Q

When is Fulcrum Therapeutics (NASDAQ:FULC) reporting earnings?

A

Fulcrum Therapeutics does not have any upcoming earnings scheduled.

Q

Is Fulcrum Therapeutics (FULC) going to split?

A

There is no upcoming split for Fulcrum Therapeutics.

Q

What sector and industry does Fulcrum Therapeutics (FULC) operate in?

A

Fulcrum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.